Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Managing Director of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.